# Study of INT-747 in Patients With Diabetes and Presumed NAFLD

> **NCT00501592** · PHASE2 · COMPLETED · sponsor: **Intercept Pharmaceuticals** · enrollment: 64 (actual)

## Conditions studied

- Diabetes Mellitus, Type II
- Fatty Liver

## Interventions

- **DRUG:** INT-747
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00501592
- **Lead sponsor:** Intercept Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2009-02
- **Final completion:** 2009-04
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2012-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00501592

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00501592, "Study of INT-747 in Patients With Diabetes and Presumed NAFLD". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00501592. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*